Log in

Nektar Therapeutics Stock Price, News & Analysis (NASDAQ:NKTR)

$15.87
-1.22 (-7.14 %)
(As of 10/15/2019 04:40 AM ET)
Today's Range
$15.70
Now: $15.87
$17.10
50-Day Range
$15.99
MA: $18.24
$21.10
52-Week Range
$15.70
Now: $15.87
$51.28
Volume2.55 million shs
Average Volume2.35 million shs
Market Capitalization$2.78 billion
P/E Ratio4.20
Dividend YieldN/A
Beta2.65
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:NKTR
CUSIP64026810
Phone415-482-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.19 billion
Cash Flow$3.94 per share
Book Value$9.92 per share

Profitability

Net Income$681.31 million
Net Margins-354.90%

Miscellaneous

Employees618
Market Cap$2.78 billion
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive NKTR News and Ratings via Email

Sign-up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.


Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) announced its earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.80) by $0.17. The biopharmaceutical company had revenue of $23.32 million for the quarter, compared to the consensus estimate of $26.65 million. Nektar Therapeutics had a negative return on equity of 25.25% and a negative net margin of 354.90%. The business's quarterly revenue was down 97.9% compared to the same quarter last year. During the same period in the previous year, the business earned $5.33 EPS. View Nektar Therapeutics' Earnings History.

When is Nektar Therapeutics' next earnings date?

Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Nektar Therapeutics.

What price target have analysts set for NKTR?

13 brokerages have issued 12 month target prices for Nektar Therapeutics' stock. Their predictions range from $16.00 to $86.00. On average, they anticipate Nektar Therapeutics' stock price to reach $37.25 in the next twelve months. This suggests a possible upside of 134.7% from the stock's current price. View Analyst Price Targets for Nektar Therapeutics.

What is the consensus analysts' recommendation for Nektar Therapeutics?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 1 sell rating, 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nektar Therapeutics.

What are Wall Street analysts saying about Nektar Therapeutics stock?

Here are some recent quotes from research analysts about Nektar Therapeutics stock:
  • 1. HC Wainwright analysts commented, "Our new 12-month, $24, vs. our prior $47 target on shares of Nektar is based on a 12-year DCF-driven, sum-of-the-parts analysis. Our DCF is driven by beta of 1.62, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2027." (8/13/2019)
  • 2. According to Zacks Investment Research, "Nektar has a promising pipeline with several candidates and regulatory updates lined up for the next several quarters. Moreover, regular partnerships have enhanced the company’s financial position. Nektar is poised to receive sales milestone payments plus royalties for Movantik, Adynovate and Neulasta, under license agreements with AstraZeneca, Takeda and Amgen, respectively. Its recent co-development deals with Lilly for NKTR-358 and Bristol-Myers for NKTR-214 are encouraging. The deals provide revenues and reduce expenses by sharing research costs. On the flip side, Nektar relies heavily on partners for revenues. Partnership-related setbacks may thus weigh heavily on the company’s results in the future. Loss estimates have narrowed ahead of the Q2 results. The company has a positive record of earnings surprises in the recent quarters." (7/31/2019)
  • 3. William Blair analysts commented, "We traveled with LeMaitre management last week as the company met with Barrington clients in Richmond, VA. This marked the second time in a month that we have spent time on the road with members of this management team and the messaging remains consistent and long-term bullish despite some short-term challenges." (6/14/2019)
  • 4. Mizuho analysts commented, "We expect these events to be important drivers for NKTR shares as we continue to believe that a majority of the company’s value lies in NKTR-214." (3/1/2019)

Has Nektar Therapeutics been receiving favorable news coverage?

News stories about NKTR stock have been trending positive on Tuesday, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Nektar Therapeutics earned a news sentiment score of 2.3 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Nektar Therapeutics.

Are investors shorting Nektar Therapeutics?

Nektar Therapeutics saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 30,900,000 shares, an increase of 8.1% from the August 30th total of 28,580,000 shares. Based on an average trading volume of 3,670,000 shares, the days-to-cover ratio is presently 8.4 days. Approximately 17.8% of the company's shares are sold short. View Nektar Therapeutics' Current Options Chain.

Who are some of Nektar Therapeutics' key competitors?

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Hawkins (HWKN), Micron Technology (MU), Puma Biotechnology (PBYI), Gilead Sciences (GILD), Incyte (INCY), Netflix (NFLX), Celgene (CELG) and Lam Research (LRCX).

Who are Nektar Therapeutics' key executives?

Nektar Therapeutics' management team includes the folowing people:
  • Mr. Howard W. Robin, CEO, Pres & Director (Age 66)
  • Mr. Gil M. Labrucherie, Sr. VP & CFO (Age 47)
  • Mr. John Nicholson, Sr. VP & COO (Age 67)
  • Dr. Maninder Hora, Sr. VP of Pharmaceutical Devel. & Chief Technical Operations Officer (Age 65)
  • Dr. Stephen K. Doberstein, Chief R&D Officer (Age 60)

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Pacer Advisors Inc. (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Dennis L Winger, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics.

Which institutional investors are selling Nektar Therapeutics stock?

NKTR stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Nektar Therapeutics company stock in the last year include Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.

Which institutional investors are buying Nektar Therapeutics stock?

NKTR stock was acquired by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. View Insider Buying and Selling for Nektar Therapeutics.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $15.87.

How big of a company is Nektar Therapeutics?

Nektar Therapeutics has a market capitalization of $2.78 billion and generates $1.19 billion in revenue each year. The biopharmaceutical company earns $681.31 million in net income (profit) each year or $3.78 on an earnings per share basis. Nektar Therapeutics employs 618 workers across the globe.View Additional Information About Nektar Therapeutics.

What is Nektar Therapeutics' official website?

The official website for Nektar Therapeutics is http://www.nektar.com/.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]


MarketBeat Community Rating for Nektar Therapeutics (NASDAQ NKTR)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  552 (Vote Outperform)
Underperform Votes:  329 (Vote Underperform)
Total Votes:  881
MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote "Outperform" if you believe NKTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NKTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel